跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Sacituzumab
首页
药物
Sacituzumab
Sacituzumab
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
EFFICACY OF ANTI-TROP-2-SN-38 ANTIBODY DRUG CONJUGATES FOR THERAPY OF TUMORS RELAPSED/REFRACTORY TO CHECKPOINT INHIBITORS
EP 3448260 A4
申请人: IMMUNOMEDICS INC
优先权: 2016
CN
EP
US
WO
5 件公开
COMBINED USE OF ANTI-TROP-2 ANTIBODY-DRUG CONJUGATE AND OTHER THERAPEUTIC AGENTS
EP 4464337 A4
申请人: SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
优先权: 2022
CN
EP
US
WO
5 件公开
BIOMARKERS FOR SACITUZUMAB GOVITECAN THERAPY
EP 4121564 A1
申请人: IMMUNOMEDICS INC
优先权: 2020
EP
US
WO
3 件公开
COMBINATION THERAPY FOR TREATING TROP-2 EXPRESSING CANCERS
EP 4499146 A1
申请人: GILEAD SCIENCES INC
优先权: 2022
EP
US
WO
3 件公开
EP 4507736 A1
申请人: GILEAD SCIENCES INC
优先权: 2022
EP
WO
2 件公开
COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-SIRPALPHA ANTIBODY
EP 4523702 A4
申请人: DAIICHI SANKYO CO LTD
优先权: 2022
EP
US
WO
3 件公开
SACITUZUMAB DRUG CONJUGATES AND PREPARATION THEREOF
EP 4680644 A1
申请人: ZYDUS LIFESCIENCES LTD
优先权: 2023
EP
US
WO
3 件公开
TREATMENT OF NON-SMALL CELL LUNG CANCER USING SACITUZUMAB GOVITECAN AND AN ANTI-PD-1 ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF
EP 4761769 A1
申请人: GILEAD SCIENCES INC
优先权: 2023
EP
US
WO
3 件公开
Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers
US 10954305 B2
申请人: IMMUNOMEDICS INC
优先权: 2016
CN
US
3 件公开
THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132)
WO 2018102212 A1
申请人: IMMUNOMEDICS INC
优先权: 2016
CN
WO
2 件公开
US 10413539 B2
申请人: IMMUNOMEDICS INC
优先权: 2017
US
2 件公开
US 2021393617 A1
申请人: IMMUNOMEDICS INC
优先权: 2021
US
2 件公开
Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
US 10918734 B2
申请人: IMMUNOMEDICS INC
优先权: 2017
CN
US
2 件公开
第 1 / 2 页
上一页
下一页
药物
反馈